Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model

Abstract

Non-alcoholic steatohepatitis (NASH) is a common chronic liver disease with no decisive treatment. The sodium glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin was developed as a new oral hypoglycemic drug, which can improve NASH via an insulin-independent glucose-lowering effect by inhibiting glucose reabsorption in the renal proximal tubules. However, ipragliflozin appears to modulate steatosis or inflammation via different pathways. To elucidate the new mechanism of ipragliflozin for the treatment of NASH, we evaluated its effects in a NASH mouse model (STAM mice) with beta cell depletion, and compared the expression of microRNAs (miRNAs) in STAM mice treated with or without ipragliflozin (16.7 μg/day for 5 weeks). Ipragliflozin reduced aspartate transaminase and alanine aminotransferase levels, along with reduced hepatic steatosis, hepatocyte ballooning, lobular inflammation, and liver fibrosis. In addition, ipragliflozin upregulated mitochondrial transport-related and antioxidant defensive system-related genes in the liver. Among 2555 mouse miRNA probes, miR-19b-3p was commonly differentially expressed with ipragliflozin treatment for 5 weeks in both the liver and serum but in different directions, with a decrease in the liver and increase in the serum. Therefore, ipragliflozin can improve NASH development likely through the antioxidative stress pathway and by regulating miR-19b-3p.

Citation: Morishita A, Tadokoro T, Fujihara S, Iwama H, Oura K, Fujita K, et al. (2022) Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model. PLoS ONE 17(2): e0261310. https://doi.org/10.1371/journal.pone.0261310

Editor: Matias A. Avila, University of Navarra School of Medicine and Center for Applied Medical Research (CIMA), SPAIN

Received: September 24, 2021; Accepted: November 30, 2021; Published: February 22, 2022

Copyright: © 2022 Morishita et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the manuscript and its Supporting information files.

Funding: The author(s) received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.

1. Introduction

Non-alcoholic steatohepatitis (NASH) is the advanced stage of non-alcoholic fatty liver disease (NAFLD) and is one of the most common chronic liver diseases worldwide with a global prevalence of approximately one-fourth of the adult population [1]. NAFLD has been recognized as the hepatic manifestation of the metabolic syndrome, whose major components are comorbidities such as obesity and type 2 diabetes mellitus (T2DM) [2–4]. In fact, liver diseases, including liver cirrhosis and hepatocellular carcinoma (HCC), represent the third leading cause of death among T2DM patients in Japan [5]. NAFLD comprises various pathological conditions ranging from simple steatosis to NASH, cirrhosis, and HCC [6]. Various drugs such as vitamin E [7, 8], peroxisome proliferator-activated receptor gamma agonists [9, 10], ursodeoxycholic acid [11, 12], antioxidants [11], insulin-sensitizing agents, glucose-lowering drugs [13–18], and lipid-lowering drugs [19–21] have been used for the treatment of NASH. Despite numerous clinical trials and tremendous efforts, there is still no definitive therapy for NASH. Lifestyle alterations, such as exercise and diet control, are currently one of the most effective therapies for NASH [22]. Although such changes bring about better outcomes, they are hard to achieve and maintain for the majority of NASH patients, resulting in poor condition requiring pharmacological therapy.

Sodium glucose cotransporter 2 (SGLT2) inhibitors have been developed as a new class of oral hypoglycemic drugs that inhibit glucose reabsorption at the proximal tubules for the treatment of T2DM [23, 24]. The oral selective SGLT2 inhibitor ipragliflozin has been shown to improve hyperglycemia, dyslipidemia, liver steatosis, oxidative stress, inflammation, and liver injury in T2DM animal models [25–27]. The mechanism of ipragliflozin in the treatment of NASH is mainly considered to be an insulin-independent glucose-lowering effect with subsequent caloric loss via the inhibition of glucose reabsorption in the renal proximal tubules [25–27]. Komiya et al. [18] demonstrated that ipragliflozin also promotes epididymal fat accumulation without worsening adipose inflammation and inhibits ectopic fat accumulation in the liver. This suggested that ipragliflozin is involved in other pathways to modulate steatosis or inflammation, including energy homeostasis and balance between adipose and non-adipose tissues.

MicroRNAs (miRNAs) are 18–22-nucleotide-long interfering, endogenous noncoding RNAs, which are abundant in the human genome, including over 1000 reported miRNA sequences [28]. MiRNAs have broad effects in regulating the expression of various genes, in which one miRNA can target and modulate more than 200 genes [29]. Several reports have recently demonstrated that the miRNA expression profile in the liver is associated with the progression of liver diseases, such as liver fibrosis, cirrhosis, and HCC [30–34]. However, what the effect of ipragliflozin is associated with miRNA expression in the NASH liver remains unexplored.

Therefore, the aim of the present study was to elucidate the effect and mechanism of ipragliflozin for the treatment of NASH using a miRNA array in a mouse model to identify differentially expressed miRNAs in NASH with and without ipragliflozin treatment.

2. Results

2.1. Biochemical and histological analyses

Serum AST and ALT levels were significantly reduced in the ipragliflozin group as compared to those of the control group (Fig 1A and 1B). In addition, serum ALP levels were slightly lower in the ipragliflozin group, although the difference was not statistically significant (Fig 1C). Fasting blood glucose levels were very high in both groups bcause pancreatic beta cells were destroyed by the streptozotocin treatment in establishment of this model (Fig 1D). Body weights between control and ipragliflozin groups were not changed (Fig 1E).

thumbnail
Download:
Fig 1. Effects of ipragliflozin on (A) ALT, (B) AST, (C) ALP, (D) fasting blood glucose, and (E) body weight (BW) in the livers of STAM mice.

Data are shown as the mean ± SD [*P < 0.025 vs. control group (n = 8) or ipragliflozin group (n = 8)].

https://doi.org/10.1371/journal.pone.0261310.g001

As shown in Fig 2, the control group developed hepatocyte steatosis, ballooning, and scattered inflammatory cell infiltration including F4/80 positive cells at 10 weeks, which were all clearly reduced in the ipragliflozin group (Fig 2A–2E). The NAFLD activity score was also significantly lower in the ipragliflozin group (Fig 2A–2C).

thumbnail
Download:
Fig 2. Livers of the STAM mice exhibited severe steatosis, many ballooning hepatocytes, and severe inflammation.

Ipragliflozin attenuated the development of hepatic steatosis (A), hepatocyte ballooning (B), lobular inflammation (C) and lobular infiltration of F4/80 positive cells (D). Data are shown as the mean ± SD (*P < 0.05). (E) Paraffin-embedded sections of the liver stained with hematoxylin and eosin and immunohistochemistry by F4/80 antibody (original magnification, 100×). (F) Paraffin-embedded sections stained with Masson’s trichrome (original magnification, 200×). (F, G, H) Ipragliflozin significantly attenuated liver fibrosis. Image analysis of the Masson’s trichrome-stained liver sections was performed using an ImageJ software. Data are shown as the mean ± SD [*P < 0.05 vs. control group (n = 8) or ipragliflozin group (n = 8)].

https://doi.org/10.1371/journal.pone.0261310.g002

In addition, liver fibrosis was also significantly diminished in the liver tissues of the ipragliflozin group as compared with those of the control group (Fig 2F–2H). We also confirmed the effect of ipragliflozin for the reduction of liver fibrosis using NAFLD fibrosis score (S1 Fig).

2.2. Ipragliflozin upregulated antioxidative genes and inflammatory markers

We further examined the effect of ipragliflozin on oxidative stress in the liver tissues. Ipragliflozin upregulated the expression of mitochondrial transport-related and antioxidant defensive system-related genes in the liver. Specifically, the mRNA levels of Sod2 and Cat were significantly increased in the ipragliflozin group relative to those of the control group (Fig 3A and 3B). In addition, the mRNA levels of Tnf and Il1b were significantly decreased in the ipragliflozin group relative to those of the control group (Fig 3C and 3D). These results suggest that ipragliflozin improves NASH development through the antioxidative stress and anti-inflammation pathway.

thumbnail
Download:
Fig 3. Ipragliflozin enhanced the antioxidative effect in the liver tissue of STAM mice.

Levels of mitochondrial transport-related and antioxidant defensive system-related genes (A) Sod2, (B) Cat, (C) TNFα, and (D) IL1β in the ipragliflozin (n = 8) and control groups (n = 8).

https://doi.org/10.1371/journal.pone.0261310.g003

2.3. miRNA expression in the liver tissue and serum samples of STAM mice

Finally, to uncover the miRNA profiles during the development of NASH, we analyzed the expression levels of 2555 mouse miRNA probes using liver tissue and serum samples from the control and ipragliflozin groups. As shown in Table 1, three miRNAs were significantly upregulated and three miRNAs were downregulated in liver tissue samples of the ipragliflozin group compared with those of the control group. Unsupervised hierarchical clustering analysis using Pearson’s correlation coefficient showed that the miRNA profile of the ipragliflozin group clustered separately from that of the control group in the liver tissue (Fig 4A). In addition, 59 miRNAs were significantly upregulated and 84 miRNAs were downregulated in serum samples of the ipragliflozin group (Table 2). Unsupervised hierarchical clustering analysis using Pearson’s correlation coefficient showed that the serum miRNA profile of the ipragliflozin group clustered separately from that of the control group (Fig 4B). Among these differentially expressed miRNAs after ipragliflozin treatment, only miR-19b-3p was commonly altered in both the liver tissue and serum samples (Fig 4C). In addition, RT-qPCR analysis confirmed that miR-19b-3p expression in the serum was significantly upregulated in the ipragliflozin group (Fig 4D).

thumbnail
Download:
Fig 4. Hierarchical clustering of the liver tissue (A) and serum (B) from STAM mice between the control and ipragliflozin groups.

Liver tissues and sera clustered according to the expression profiles of six differentially expressed miRNAs between groups. The analyzed samples are reported in columns and the miRNAs are presented in rows. The miRNA clustering tree is shown on the left, and the sample clustering tree appears at the top. The color scale shown at the top indicates the relative expression level of miRNAs, with red representing a high expression level and blue representing a low expression level. (C) Among 2555 miRNAs analyzed, miR-19b-3p was significantly upregulated in the serum and downregulated in the liver tissue of STAM mice after ipragliflozin administration. (D) RT-qPCR results showing that miR-19b-3p expression was significantly upregulated in the serum of STAM mice treated with ipragliflozin. Data are shown as the mean ± SD [*P < 0.05 vs. control group (n = 8) or ipragliflozin group (n = 8)].

https://doi.org/10.1371/journal.pone.0261310.g004

thumbnail
Download:
Table 1. miRNA expression profile in the liver tissue of mice treated with ipragliflozin.

https://doi.org/10.1371/journal.pone.0261310.t001

thumbnail
Download:
Table 2. miRNA expression profile in the serum of mice treated with ipragliflozin.

https://doi.org/10.1371/journal.pone.0261310.t002

3. Discussion

The prevalence of NAFLD and NASH has increased worldwide [35–37]. T2DM is an important risk factor for NAFLD; Matteoni et al. [38] demonstrated that 33–50% of T2DM patients have NAFLD. Although the antidiabetic drug pioglitazone, which is an insulin-sensitizing agent, has a beneficial effect for NASH, long-term outcomes about its efficacy and safety, including the side effects of cardiovascular disease, congestive heart failure, bladder cancer, and bone loss, have not yet been elucidated [39]. To date, no effective drug for NASH has been discovered; thus, it is critical to investigate an effective therapy for patients with NASH. Therefore, we explored the effects of ipragliflozin on NASH and the underlying mechanism using STAM mice.

Our results demonstrated that ipragliflozin had a therapeutic effect on NASH in STAM mice. Ipragliflozin has been reported to improve hyperglycemia by inducing the urinary excretion of glucose [40, 41]. Ipragliflozin has been shown to dose-dependently increase urinary glucose excretion in various types of mice, including normal and streptozotocin–nicotinamide-induced diabetic mice [25–27, 42]. In the present study, ipragliflozin improved the lobular inflammation score, although our STAM mouse model is an insulin-deficient NASH model. Hence, we hypothesize that ipragliflozin improved hyperglycemia, liver inflammation, and liver fibrosis through not only urinary glucose excretion but also other mechanisms. Reactive oxygen species (ROS) are recognized as an origin of oxidative stress and produced through the metabolism of free fatty acids in mitochondria, microsomes, and peroxisomes. Migration of the electrons supplied to the mitochondrial respiratory chain eventually reach the cytochrome C oxidase, combining with oxygen and protons to form water [43]. However, some of these electrons leak out and form the superoxide anion radical. SOD2 dismutes this radical into hydrogen peroxide, which is detoxified into water by GPXS and CAT [44]. Low levels of ROS are associated with important cellular processes. Therefore, proper control of oxidative stress and a balance between oxidative and antioxidative responses are pivotal [45]. Excess superoxide can be produced in damaged mitochondria by electron leakage and this excess is converted to hydrogen peroxide by SOD2. Although GPXS or CAT can metabolize hydrogen peroxide to nontoxic H2O, iron-mediated Fenton and/or Haber-Weiss reactions produce highly reactive and toxic hydroxyl radicals. The levels of iron which is an inducer of oxidative stress are increased in NASH. Reduced iron levels brings about the improvement of liver functions in patients with chronic liver diseases [46]. In our present study, SOD2 and CAT expression was upregulated in the liver after ipragliflozin administration (Fig 3A and 3B). Thus, most mitochondrial ROS might be detoxified by ipragliflozin. These data suggest that ipragliflozin might inhibit NASH development in the liver, reinforcing the activity of the key ROS-scavenging antioxidant enzymes SOD2 and CAT directly or indirectly.

Furthermore, ipragliflozin is said to inhibit SGLT1 and SGLT2. Since the intestinal and hepatic axes are known to play an important role in NAFLD/NASH, we also examined the expression of SGLT1 and SGLT2 in the intestinal cells of STAM mice. As a result, the expression of SGLT1 was upregulated, but the expression of SGLT2 was not expressed in small intestinal cells (S4 Fig). Surprisingly, ipragliflozin treatment resulted in the expression of p21 in intestinal cells in vitro and in vivo (S5 and S6 Figs). These results suggest that ipragliflozin may be involved in the proliferation of intestinal cells, resulting in changes in enterohepatic immunity. Surprisingly, SGLT2 was not expressed in normal liver, but was expressed in various HCC cell lines (S7 Fig). Therefore, our results suggest that ipragliflozin does not act directly on the normal liver, but inhibits the development of NASH by suppressing SGLT2 in the kidney and SGLT1 in the small intestine.

Among the upregulated miRNAs identified in the serum, miR-19b-3p was found to be significantly downregulated in the liver following ipragliflozin treatment in STAM mice; however, miR-34a-5p, miR-149-5p, and miR-122-5p were not changed in the serum (S2 Fig) and liver tissue (S3 Fig). There are several potential reasons for the increase of miR-19b-39 in the serum and its decrease in the liver, including (i) leaked miR-19b-3p increased due to the destruction of hepatocytes and (ii) miR-19b-3p was secreted from hepatocytes as a circulating miRNA. Recently, serum miR-19b-3p up-regulation was shown to alleviate the lipopolysaccharide (LPS)-induced inflammatory response of human umbilical vein endothelial cells, thereby inhibiting the LPS-induced expression of the pro-inflammatory cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-α [47]. In addition, Duan et al. [48] demonstrated that miR-19b-3p attenuated IL-1β-induced extracellular matrix degradation and inflammatory injury. These reports suggest that ipragliflozin might have attenuated NASH development through not only the improvement of hyperglycemia by inducing the urinary excretion of glucose but also by modulation of miR-19b-3p to inhibit IL-6 and TNF-α expression. Furthermore, circulating miR-19b-3p has been reported to be involved in liver fibrosis via inhibition of C–C motif chemokine receptor (CCR2), indicating that up-regulation of circulating miR-19b-3p suppresses liver fibrogenesis via the regulation of inflammation [49].

In conclusion, we confirmed that ipragliflozin improves NASH development and identified a new mitochondrial pathway and a key miRNA that were modulated by ipragliflozin in a NASH mouse model. Our findings might provide a simple and novel therapeutic strategy for NASH.

4. Materials and methods

4.1. Animals and experimental design

STAM mice, a NASH-cirrhosis-hepatocarcinogenic model, were purchased from Stelic Institute & Co., Inc. (Tokyo, Japan). This mouse model progresses from NAFLD to NASH at 8 weeks of age and develops HCC at 16 weeks of age [50]. In brief, for model establishment, C57BL/6J male mice were injected with 20 μL solution (10 mg/mL) of streptozotocin (Sigma-Aldrich Japan, Tokyo, Japan) 2 days after birth to destroy pancreatic beta cells, and were subsequently fed a high-fat diet (HFD-32; CLEA-Japan, Tokyo, Japan). For NASH experiments, 5-week-old male STAM mice were divided into two experimental groups: the control group was fed the HFD and the ipragliflozin group was fed the HFD mixed with 16.7 μg/day of ipragliflozin (Astellas Pharma Inc., Tokyo, Japan) for 5 weeks. The feed was replaced 3 times per week, so that it was kept dry, as HFDs tend to retain moisture. After 10 weeks, the mice were sacrificed using carbon dioxide. Blood samples were obtained from the right atrium by cardiac puncture and the livers were excised. The livers were cut into pieces and fixed in 10% formalin for histological analysis or fresh-frozen in liquid nitrogen and stored at –80°C in a freezer until use. The animals had free access to water and food and were maintained under specific pathogen-free conditions in a temperature-controlled animal facility with a 12-h light-dark cycle. All protocols and procedures conformed to the guidelines of the Kagawa University Committee for Care and Use of Laboratory Animals and were approved by the Animal Experiments Ethics Committee of Kagawa University (approved number 15145). This study was carried out in compliance with the ARRIVE guidelines.

4.2. Measurement of fasting blood glucose, plasma aminotransferases, and triglycerides

The levels of fasting blood glucose were measured after 12 h of fasting using a blood glucose meter (GT1820; Arkray Inc., Kyoto, Japan). Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) levels were determined by standard methods at Shikoku Chuken Central Biolaboratory (Takamatsu, Japan).

4.3. Histological analysis of the liver

Sections of formalin-fixed livers were used for hematoxylin-eosin and Masson’s trichrome staining for pathological analysis. NAFLD activity was assessed by the NAFLD activity score, as described by Kleiner et al., with separate scores for steatosis (0–3), hepatocellular ballooning (0–2), and lobular inflammation (0–3) [51]. All liver specimens were assessed by two hepatologists (AM and TM) blinded to the identities of the study groups.

4.4. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

The whole RNA extracted from murine liver using RNeasy kit (Qiagen) was used for RT-qPCR with manufacturer’s directions. Each extracted RNA was reverse-transcribed with a TaqMan Reverse Transcription kit (Life Technologies Japan) and quantified using TaqMan Gene Expression Assay (Applied Biosystems, Foster City, USA) with the manufacturer’s directions. We analyzed the relative quantification of targeting mRNAs by using the comparative cycle threshold (CT) method (2−ΔΔCT). Actb was quantified as a house keeping gene.

Circulating miRNA purified from murine serum using the QIAGEN miRNeasy serum-plasma kit (Qiagen K.K., Tokyo) and tissue miRNA extracted from murine liver using the miRNeasy Mini Kit (Qiagen, Hilden, Germany) were used for RT-qPCR with the manufacturer’s directions. Each extracted miRNA was reverse-transcribed with TaqMan MicroRNA Reverse Transcription kit (Life Technologies Japan, Tokyo). For the relative quantification of serum miRNA, Caenorhabditis elegans miR-39 (cel-miR-39) was spiked in each sample as an external control. The serum miRNA was quantified using the TaqMan MicroRNA assay with the manufacturer’s directions. We analyzed the relative quantification of targeting miRNAs by using the comparative cycle threshold (CT) method (2−ΔΔCT) with spiked cel-miR-39 serving as an external control. For the quantification of liver tissue miRNA, Rnu6b was used as an internal control for relative quantification.

4.5. miRNA array

Whole miRNA extracted from the serum or liver tissues using a miRNeasy Mini Kit (Qiagen, Hilden, Germany) with the manufacturer’s directions was determined by an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). The miRNA samples were measured using RNA 6000 Nano Kit (Agilent Technologies) and labeled by miRCURYHy3/Hy5 Power Labeling Kit. Subsequently these miRNAs were hybridized to a mouse miRNA Oligo chip (v. 21.0; Toray Industries, Tokyo, Japan). Hybridized miRNAs were detected using 3D-Gene Scanner 3000 (Toray Industries) and analyzed by 3D-Gene extraction version 1.2 software (Toray Industries). Comprehensive microarray analysis of miRNA expression between the control and ipragliflozin groups were performed using GeneSpring GX 10.0 software (Agilent Technologies). We used quantile normalization for making the background identical. Differentially expressed miRNAs were verified using the Mann-Whitney U test and the furthest-neighbor method with the absolute uncentered Pearson’s correlation coefficient as a metric was used for hierarchical clustering. The base-2 logarithm of the intensity was median-centered for each row in a heat map which was created using the relative expression intensity for each miRNA.

4.6. Statistical analysis

All analyses were conducted using computer-assisted GraphPad Prism 8.4.2 (GraphPad Software, San Diego, CA, USA). Paired analysis between the groups was conducted using Student’s t test. P < 0.05 was considered to indicate a significant difference between the groups.

5. Conclusions

Our present study demonstrated that ipragliflozin improved NASH development and identified a new mitochondrial pathway and a key miRNA that were regulated by ipragliflozin in a NASH mouse model. Ipragliflozin also affected to the small intestine for preventing NASH development. Therefore, our findings might provide a novel therapeutic strategy for NASH.

Supporting information

S1 Fig. Ipragliflozin attenuated liver fibrosis using NAFLD fibrosis score.

https://doi.org/10.1371/journal.pone.0261310.s001

(TIF)

S2 Fig. SGLT1 and SGLT2 expression in the small intestine.

https://doi.org/10.1371/journal.pone.0261310.s002

(TIF)

S3 Fig. p21 mRNA expression by ipragliflozin in small intestine cancer cell line.

https://doi.org/10.1371/journal.pone.0261310.s003

(TIF)

S4 Fig. p21 expression in the small intestine between Control and Ipragliflozin group.

https://doi.org/10.1371/journal.pone.0261310.s004

(TIF)

S5 Fig. Microarray data analysis revealed that miR-34a-5p, miR-149-5p, and miR-122-5p expressions were not significantly changed in the serum of STAM mice treated with ipragliflozin.

https://doi.org/10.1371/journal.pone.0261310.s005

(TIF)

S6 Fig. Microarray data analysis revealed that miR-34a-5p, miR-149-5p, and miR-122-5p expressions were not significantly changed in the liver of STAM mice treated with ipragliflozin.

https://doi.org/10.1371/journal.pone.0261310.s006

(TIF)

S7 Fig. SGLT2 expression in hepatocellular carcinoma cell lines.

https://doi.org/10.1371/journal.pone.0261310.s007

(TIF)

S1 File.

https://doi.org/10.1371/journal.pone.0261310.s008

(XLSX)

S2 File.

https://doi.org/10.1371/journal.pone.0261310.s009

(XLSX)

S3 File.

https://doi.org/10.1371/journal.pone.0261310.s010

(XLSX)

S4 File.

https://doi.org/10.1371/journal.pone.0261310.s011

(XLSX)

S5 File.

https://doi.org/10.1371/journal.pone.0261310.s012

(XLSX)

S6 File.

https://doi.org/10.1371/journal.pone.0261310.s013

(XLSX)

S7 File.

https://doi.org/10.1371/journal.pone.0261310.s014

(XLSX)

S8 File.

https://doi.org/10.1371/journal.pone.0261310.s015

(XLSX)

S9 File.

https://doi.org/10.1371/journal.pone.0261310.s016

(XLSX)

References

  1. 1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. pmid:26707365.
  2. 2. Jimba S, Nakagami T, Takahashi M, Wakamatsu T, Hirota Y, Iwamoto Y, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med. 2005;22(9):1141–5. pmid:16108839.
  3. 3. Corey KE, Kaplan LM. Obesity and liver disease: the epidemic of the twenty-first century. Clin Liver Dis. 2014;18(1):1–18. pmid:24274861.
  4. 4. Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014;18(1):19–31. pmid:24274862.
  5. 5. Nakamura J, Kamiya H, Haneda M, Inagaki N, Tanizawa Y, Araki E, et al. Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: Report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig. 2017;8(3):397–410. pmid:28349643.
  6. 6. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37(5):1202–19. pmid:12717402.
  7. 7. Sumida Y, Niki E, Naito Y, Yoshikawa T. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res. 2013;47(11):869–80. pmid:24004441.
  8. 8. Sumida Y, Nakashima T, Yoh T, Furutani M, Hirohama A, Kakisaka Y, et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol. 2003;38(1):32–8. pmid:12480557.
  9. 9. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135(4):1176–84. pmid:18718471.
  10. 10. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355(22):2297–307. pmid:17135584.
  11. 11. Mitsuyoshi H, Nakashima T, Sumida Y, Yoh T, Nakajima Y, Ishikawa H, et al. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun. 1999;263(2):537–42. pmid:10491327.
  12. 12. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39(3):770–8. pmid:14999696.
  13. 13. Sumida Y, Seko Y, Yoneda M, Japan Study Group of N. Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res. 2017;47(4):266–80. pmid:28019064.
  14. 14. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90. pmid:26608256.
  15. 15. Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M, et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res. 2015;45(3):269–78. pmid:24796231.
  16. 16. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–44. pmid:27633186.
  17. 17. Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Semaglutide, lipid-lowering drugs, and NAFLD. Lancet Diabetes Endocrinol. 2017;5(5):329–30. pmid:28434490.
  18. 18. Komiya C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, Shimazu N, et al. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS One. 2016;11(3):e0151511. pmid:26977813.
  19. 19. Yoneda M, Fujita K, Nozaki Y, Endo H, Takahashi H, Hosono K, et al. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study. Hepatol Res. 2010;40(6):566–73. pmid:20412324.
  20. 20. Park H, Shima T, Yamaguchi K, Mitsuyoshi H, Minami M, Yasui K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol. 2011;46(1):101–7. pmid:20658156.
  21. 21. Loomba R, Sirlin CB, Ang B, Bettencourt R, Jain R, Salotti J, et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology. 2015;61(4):1239–50. pmid:25482832.
  22. 22. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121–9. pmid:19827166.
  23. 23. Chao EC, Henry RR. SGLT2 inhibition—a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551–9. pmid:20508640.
  24. 24. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733–94. pmid:21527736.
  25. 25. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715(1–3):246–55. pmid:23707905.
  26. 26. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J Pharmacol Sci. 2012;120(1):36–44. pmid:22971845.
  27. 27. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol. 2014;66(7):975–87. pmid:24533859.
  28. 28. Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Science. 2005;309(5740):1519–24. pmid:16141061.
  29. 29. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37(5):495–500. pmid:15806104.
  30. 30. Ramachandran S, Ilias Basha H, Sarma NJ, Lin Y, Crippin JS, Chapman WC, et al. Hepatitis C virus induced miR200c down modulates FAP-1, a negative regulator of Src signaling and promotes hepatic fibrosis. PLoS One. 2013;8(8):e70744. pmid:23950995.
  31. 31. Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K, et al. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut. 2012;61(11):1600–9. pmid:22267590.
  32. 32. Bandyopadhyay S, Friedman RC, Marquez RT, Keck K, Kong B, Icardi MS, et al. Hepatitis C virus infection and hepatic stellate cell activation downregulate miR-29: miR-29 overexpression reduces hepatitis C viral abundance in culture. J Infect Dis. 2011;203(12):1753–62. pmid:21606534.
  33. 33. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology. 2011;53(1):209–18. pmid:20890893.
  34. 34. Pirola CJ, Fernandez Gianotti T, Castano GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64(5):800–12. pmid:24973316.
  35. 35. Sanyal AJ, American Gastroenterological A. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1705–25. pmid:12404245.
  36. 36. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23. pmid:12668987.
  37. 37. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122(6):1649–57. pmid:12016429.
  38. 38. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413–9. pmid:10348825.
  39. 39. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55(4):885–904. pmid:22278337.
  40. 40. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85. pmid:20427778.
  41. 41. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298(10):1180–8. pmid:17848652.
  42. 42. Hayashizaki-Someya Y, Kurosaki E, Takasu T, Mitori H, Yamazaki S, Koide K, et al. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats. Eur J Pharmacol. 2015;754:19–24. pmid:25701721.
  43. 43. Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol. 2011;54(4):773–94. pmid:21145849.
  44. 44. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion. 2006;6(1):1–28. pmid:16406828.
  45. 45. Mittler R, Vanderauwera S, Suzuki N, Miller G, Tognetti VB, Vandepoele K, et al. ROS signaling: the new wave? Trends Plant Sci. 2011;16(6):300–9. pmid:21482172.
  46. 46. Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, Unalp-Arida A, et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology. 2011;53(2):448–57. pmid:21274866.
  47. 47. Xu H, Liu X, Ni H. Clinical significance of miR-19b-3p in patients with sepsis and its regulatory role in the LPS-induced inflammatory response. Eur J Med Res. 2020;25(1):9. pmid:32188465.
  48. 48. Duan L, Duan D, Wei W, Sun Z, Xu H, Guo L, et al. MiR-19b-3p attenuates IL-1beta induced extracellular matrix degradation and inflammatory injury in chondrocytes by targeting GRK6. Mol Cell Biochem. 2019;459(1–2):205–14. pmid:31227976.
  49. 49. Lan T, Li C, Yang G, Sun Y, Zhuang L, Ou Y, et al. Sphingosine kinase 1 promotes liver fibrosis by preventing miR-19b-3p-mediated inhibition of CCR2. Hepatology. 2018;68(3):1070–86. pmid:29572892.
  50. 50. Fujii M, Shibazaki Y, Wakamatsu K, Honda Y, Kawauchi Y, Suzuki K, et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol. 2013;46(3):141–52. pmid:23430399.
  51. 51. Kleiner DE, Makhlouf HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis. 2016;20(2):293–312. pmid:27063270.